Over the past decade, China, once hailed as a "pharmaceutical giant," has undergone a profound and even revolutionary transformation in its generic drug industry. This transformation does not signify the complete demise of the industry, but rather represents the "collapse" of outdated business models and the reshaping of industrial ecosystems. This essay aims to systematically elucidate the underlying logic behind China's generic drug industry transitioning from its "golden age" to "structural collapse" by analyzing the evolution of policy regulations, internal bottlenecks in R&D innovation, external barriers in international trade, and the intensifying market competition. It also explores its future development trajectory.

I. The double-edged sword of policy: from "barbaric growth" to "profit bottoming out"

The fundamental transformation of China's generic drug industry began with the restructuring of top-level design. In the past, lax approval standards and market access mechanisms gave rise to numerous low-level, homogeneous generic drug enterprises, resulting in an industry characterized by "numerous, small, scattered, and chaotic" operations. However, since 2015, a series of policy measures aimed at "improving quality and controlling costs" have completely overturned the survival rules of generic drugs.

First, the "consistency evaluation" policy represents a revolutionary elevation of quality thresholds. In 2016, the General Office of the State Council issued the "Opinions on Conducting Consistency Evaluations for the Quality and Efficacy of Generic Drugs," requiring generic drugs to meet the same standards as originator drugs in both quality and efficacy. This policy directly eliminated numerous small and medium-sized enterprises with insufficient technical capabilities and inability to bear the high evaluation costs, achieving the first large-scale industrial clearance from the supply side. It marks the shift in China's generic drug regulation from "copying the form" to "copying the essence," with quality becoming a prerequisite for corporate survival.

Secondly, the "National Centralized Drug Procurement" (abbreviated as "Volume-based Procurement" or VBP) has dealt a fatal blow to business models. Since the implementation of the "National Centralized Drug Procurement and Use Pilot Program" in 2019, this volume-based procurement mechanism has established a "state-level bulk purchasing" system. By applying the principle of "volume-for-price," it has driven drug prices to rock-bottom levels. This system has completely dismantled the previous sales model of generic drugs that relied on "high pricing and high kickbacks," severely compressing their profit margins. Market analysis reports consistently indicate that generic drug prices will experience a cliff-like decline between 2020 and 2025. Only through massive cost advantages or economies of scale can pharmaceutical companies survive on the brink of marginal profits or even losses.

Meanwhile, reforms in drug evaluation and approval systems—including the 2015 "Guidelines on Reforming Drug and Medical Device Review and Approval Systems" and the 2020 updated "Drug Registration Management Measures" —have explicitly encouraged innovation through policy directives. These reforms have accelerated the approval process for innovative drugs while imposing stricter requirements on generic drug applications, further squeezing the market space for low-end generics. It can be said that this policy "combination punch" has created a new competitive landscape: only high-quality, low-cost generics can survive, marking the end of the era when profiteering relied on information asymmetry and channel advantages.

II. Life and Death of Transformation: The "Gap between youth and old" on the Road to Innovation

Under the policy pressure, the transformation from generic drugs to innovative drugs has become a common consensus in the industry. However, for most generic drug companies accustomed to "making quick money", this transformation path is full of thorns, exposing their serious lack of r&d and innovation capabilities.

China's pharmaceutical industry has long been characterized by a "heavy emphasis on imitation and a neglect of R&D" in its foundational development. Among the approximately 4,000 domestic pharmaceutical companies, over 90% are generic drug manufacturers, with their R&D investment as a percentage of sales revenue far below that of developed countries. Compared to international pharmaceutical giants that typically invest over 20% in R&D intensity, the average level of domestic enterprises has remained persistently low for a long time, lacking core capabilities for original innovation and tackling high-difficulty challenges.

This prolonged "R&D hiatus" has created a severe transformation dilemma. On one hand, volume-based procurement has drastically squeezed corporate profits, leaving insufficient cash flow to fund long-term, high-risk innovative drug development. On the other hand, such R&D requires deep scientific expertise, talent reserves, and technical platforms – capabilities that generic drug manufacturers cannot achieve overnight. Although some industry leaders have successfully transitioned and increased R&D investments annually, small and medium-sized generic drug companies, which dominate the sector, find themselves trapped in a "wait or perish" dilemma. They lack both the financial capacity to cover costly consistency evaluations and the resources to sustain the capital-intensive innovation cycle. This talent gap in innovation has led numerous enterprises to be swept away by industrial upgrading waves, becoming protagonists in the "disastrous transformation" narrative.

Third, the obstacle to going overseas: the "patent cliff" in the international market

In the context of fierce domestic market competition, "going overseas" was once seen as a hope for generic drug companies to seek new growth points. However, the entry barriers in international markets, especially in mature markets in Europe and the United States, are much higher than those in China, among which the most core is the patent barrier.

The "patent cliff" for originator drugs has created market opportunities for generic drugs, but it also means that generic drug companies must "dance" within a complex patent network. In recent years, as Chinese pharmaceutical companies have attempted to challenge overseas markets, legal disputes involving patent infringement have significantly increased. For example, international pharmaceutical giants such as Boehringer Ingelheim and others have repeatedly initiated patent infringement lawsuits against Chinese generic drug companies attempting to enter the market between 2020 and 2025, and successfully obtained injunctions. These cases highlight the lack of experience among Chinese companies in international patent layout, litigation response, and intellectual property strategy.

More importantly, the intellectual property protection environment in China is undergoing profound changes. The "drug patent linkage system" introduced by China aims to resolve patent disputes between originator drugs and generic drugs at an early stage. Although this system balances innovation and imitation, it has significantly increased the litigation risks and uncertainties faced by generic drugs before market approval. For instance, the "Mabavir" drug patent linkage case adjudicated by the Supreme People's Court in 2023 clarified the criteria for determining whether generic drug technical solutions fall within the scope of patent protection, providing originator drug companies with stronger patent protection tools.

Therefore, both the international patent litigation faced by generic drug companies when "going global" and the increasingly stringent domestic patent protections they encounter when "staying local" have further constrained their operational space. Without robust patent analysis and challenge capabilities, these companies struggle to establish themselves in both domestic and international markets, making their eventual demise inevitable.

IV. The Red Sea of Survival: winner-takes-all under extreme compression

Policy, R&D, and patent disputes ultimately converge in market competition, plunging the generic drug industry into a cutthroat "red ocean" scenario. The volume-based procurement system operates on a winner-takes-all principle: successful bidders secure the lion's share of market share, while unsuccessful bidders receive negligible returns. This mechanism drives an exceptionally brutal price war that leaves no room for negotiation.

Market analysis reports reveal that since 2020, generic drugs included in national centralized procurement programs have seen dramatic price reductions, with some varieties dropping over 90%. These steep cuts no longer represent mere cost-cutting but have become a critical test of manufacturers 'cost control capabilities. The traditional model of relying on doctors' prescriptions to offset marketing expenses through high profit margins has now completely collapsed.

The market is undergoing rapid restructuring with striking intensity. Industry consolidation has accelerated significantly, as a few large enterprises boasting scaled production, exceptional cost control, and robust supply chain management continue to expand their market share through centralized procurement contracts. Meanwhile, numerous small and medium-sized generic drug manufacturers struggling in price wars have seen their market positions eroded at breakneck speed, facing shutdowns, acquisitions, or even bankruptcy. This price-driven competition has accelerated the elimination of outdated production capacities, serving as the most tangible manifestation of the "Generic Drug Demise Chronicles".

 conclusion 

In conclusion, the "Disintegration of Generic Drugs" does not mark the end of China's generic drug industry, but rather represents a fundamental iteration in its development model. Looking back at 2025 today, we can clearly see that the policy combination centered on consistency evaluation and volume-based procurement has completely reshaped industry rules, propelling the sector from a low-level "wild growth" phase to a stage of high-quality, cost-effective integration. However, the inherent shortcomings in corporate R&D innovation capabilities and the stringent patent barriers faced in both domestic and international markets have made their transformation process arduous. Ultimately, the brutal market price competition became the final straw that broke the old model.

This profound transformation is painful, but it is also the necessary growing pains for China to transition from a "pharmaceutical giant" to a "pharmaceutical powerhouse". In the future, the surviving generic drug companies will be those "super players" that possess world-class quality standards, extreme cost control capabilities, and certain technological barriers (such as high-end, hard-to-imitate generic drugs). The broader future belongs to Chinese pharmaceutical enterprises that have successfully bridged the transformation gap and established core competitiveness in innovative drug development. The old era of generic drugs has "perished", and a new pharmaceutical era driven by innovation and rooted in quality is unfolding. Therefore, the "Annals of Generic Drug Demise" does not signify the demise of "generic drugs" themselves, but rather the brutal era that relied on information gaps, channel relationships, and audacity to profit. This is a "precision targeted elimination" against outdated business models.

 consult 

1. China Generic Drug CXO Market Research Report-Frost & Sullivan Consulting Company 2023.04

2. Pharmaceutical Investment Strategy under the New Policy Situation (2020)

3.China: Trends & Developments

4. Research on pharmaceutical patent challenges under the early settlement mechanism of pharmaceutical patent disputes

5.2025 Health Industry Law White Paper

Disclaimer: This article is only for the purpose of knowledge exchange, sharing and popular science, does not involve commercial publicity, and is not a relevant medical guidance or medication advice. If there is any infringement, please contact us to delete.

Our products are recommended:

1.2589531-70-2  https://www.bicbiotech.com/product_detail.php?id=6414

2.2589534-23-4  https://www.bicbiotech.com/product_detail.php?id=6415

3.2589531-73-5  https://www.bicbiotech.com/product_detail.php?id=6416

4.2548-29-0  https://www.bicbiotech.com/product_detail.php?id=6417

5.372198-41-9  https://www.bicbiotech.com/product_detail.php?id=6418